Therapeutic use of anti-cs1 antibodies

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01) A61P 35/02 (2006.01) C07K 14/705 (2006.01)

Patent

CA 2523001

The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen- binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.

La présente invention concerne des antagonistes de CS1 qui se lient à CS1 et qui neutralisent au moins une activité biologique de CS1. Cette invention se rapporte également à une composition pharmaceutique renfermant de tels anticorps ou des fragments à liaison antigénique de ces anticorps, et à une méthode de prévention ou de traitement des états pathologiques comprenant les maladies auto-immunes et le cancer, chez un sujet nécessitant un tel traitement ou une telle prévention, qui consiste à administrer audit sujet, une quantité efficace de tels antagonistes.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Therapeutic use of anti-cs1 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic use of anti-cs1 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of anti-cs1 antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2075449

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.